RecruitingNot Applicable

LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology

Australia300 participantsStarted 2023-02-28

Plain-language summary

This study will develop a whole-of-body markerless tracking method for measuring the motion of the tumour and surrounding organs during radiation therapy to enable real-time image guidance. Routinely acquired patient data will be used to improve the training, testing and accuracy of a whole-of-body markerless tracking method. When the markerless tracking method is sufficiently advanced, according to the PI of each of the data collection sites, the markerless tracking method will be run in parallel to, but not intervening with, patient treatments during data acquisition.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Will receive radiation therapy for brain, breast, head and neck, kidney, liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment at a participating centre. * Will receive CT planning, and a cone beam CT scan for at least one fraction of radiation therapy. * Will receive intrafraction x-ray imaging for the liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment. As intrafraction imaging is not common standard of care for brain, breast, head and neck and kidney cancer treatments there is no requirement to have intrafraction x-ray imaging data for these anatomical sites. * Provides written informed consent. Exclusion Criteria: * Less than 18 years of age

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1This trial is testing AI-based 'markerless tracking' during radiotherapy — can you explain what that means compared to how my tumor is currently tracked during radiation treatment, and why that difference matters for my care?
2Since this study is listed as 'Phase NA,' it seems more focused on measuring accuracy of a technology than testing a new drug or dose — does that mean there's less direct medical risk to me as a participant, or are there still concerns I should weigh?
3The trial covers a wide range of cancers including my diagnosis — can you tell me specifically how the markerless tracking would be used for my tumor type and location, and whether my anatomy or treatment site makes me a good or poor candidate for this kind of AI monitoring?
4If I participate in this trial, would my actual radiation treatment plan or delivery change in any way, or would the AI tracking system be running in the background without affecting how I'm treated?
5Would joining this study delay my start of standard radiotherapy at all, and if standard treatment is already well-established for my diagnosis, is there a reason to consider participating versus just proceeding with the usual approach?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Accuracy of markerless tracking

Timeframe: 3 years

Trial details

NCT IDNCT05184790

SponsorUniversity of Sydney

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2028-01-31

Contact for this trial

Shona Silvester

+61 2 8627 1185 shona.silvester@sydney.edu.au

View on ClinicalTrials.gov More Arrhythmias, Cardiac trials